Helyx Industries was born out of a paradigm shift: from Ulisse Biomed to an integrated industrial group with three complementary divisions — Hyris, Vytro and Mytho — covering the entire spectrum of molecular diagnostics, from distributed qPCR to customised NGS. This article recounts the transformation, the new structure and the vision that now guides Helyx's evolution.

Multiplex PCR is revolutionising HPV screening thanks to its ability to identify multiple high-risk genotypes in a single test, improving sensitivity and accuracy. Recent evidence confirms the clinical value of self-sampling in enhancing screening adherence. A combined approach could significantly reduce the incidence of cervical cancer.

Distributed PCR reduces TCO by bringing testing closer to the point of care: less logistics, faster TAT, optimised resources. With Ulisse Biomed's as-a-Service models and Hyris System™, costs become variable and operational efficiency increases.

Multiplex PCR allows for rapid analysis of the human microbiota. This approach opens up a new era for diagnosis and treatment of chronic diseases, and for the development of personalised nutraceuticals.